miniABCA4 / Astellas - LARVOL DELTA

Astellas Completes Acquisition of Iveric Bio (Astellas Press Release) - "Astellas Pharma Inc...today announced that it has successfully completed the acquisition of IVERIC bio, Inc....with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the 'Acquisition'). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary...'We are very pleased to welcome Iveric Bio and its highly experienced professionals in the ophthalmology field, as a member of Astellas'...Acquisition amount US$40 per share, approximately US$5.9 billion in the aggregate...Astellas is currently reviewing the impact that the completion of the transactions described above may have on its consolidated business forecast for the current fiscal year ending March 31, 2024 and will make any necessary disclosure in accordance with applicable requirements."

M&A • Macular Degeneration • Ophthalmology • Wet Age-related Macular Degeneration

[VIRTUAL] MiniABCA4 Gene Replacement Therapy: A Single Vector-Based and Mutation-Independent Approach to Treat ABCA4-Associated Retinal Disease (ASGCT 2021) - "In addition, diminished autofluorescence is well correlated with immunofluorescent detection of miniABCA4 expression in the restored photoreceptor outer segments, which are lost in the late stage of Stargardt disease. Our preliminary results indicate that the miniABCA4 approach with conventional AAV vectors may have the potential for mutation-independent gene therapy STGD1 patients."

Gene Therapies • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders